peptide-yy and Osteoporosis

peptide-yy has been researched along with Osteoporosis* in 2 studies

Reviews

2 review(s) available for peptide-yy and Osteoporosis

ArticleYear
The role of NPY and ghrelin in anorexia nervosa.
    Current pharmaceutical design, 2012, Volume: 18, Issue:31

    Complex mechanisms have evolved that control feeding and energy homeostasis in mammals. Centrally, particularly in the hypothalamus, numerous neurotransmitters have been identified that regulate appetite and energy homeostasis. On the other hand, hormones released from the gut signal states of hunger and satiety to the brain. From the large number of players involved in this interplay, peptides from the neuropeptide Y (NPY) family are unique, with the predominantly neuronally expressed NPY being one of the most strongly stimulating agents for food intake while its two other closely related family members peptide YY (PYY) and pancreatic polypeptide (PP) released from the gut induce satiety. Another major player in this circuitry is ghrelin, which is released from the stomach and is the only known hormone that signals hunger to the brain. It is doing this by stimulating hypothalamic NPY production and release, subsequently leading to increased appetite and feeding behaviour. Deregulation of these processes can lead to either the development of obesity or the other extreme, anorexia. The aim of this review is to summarize the recent literature on NPY and ghrelin and its involvement in anorexia nervosa.

    Topics: Animals; Anorexia Nervosa; Appetite Regulation; Bone and Bones; Energy Metabolism; Ghrelin; Homeostasis; Humans; Neurons; Neuropeptide Y; Osteoporosis; Pancreatic Polypeptide; Peptide YY; Protein Precursors; Receptors, Ghrelin; Receptors, Neuropeptide Y; Signal Transduction

2012
Anorexia nervosa and osteoporosis.
    Reviews in endocrine & metabolic disorders, 2006, Volume: 7, Issue:1-2

    Anorexia nervosa (AN), a condition of severe undernutrition, is associated with low bone mineral density (BMD) in adults and adolescents. Whereas adult women with AN have an uncoupling of bone turnover markers with increased bone resorption and decreased bone formation markers, adolescents with AN have decreased bone turnover overall. Possible contributors to low BMD in AN include hypoestrogenism and hypoandrogenism, undernutrition with decreased lean body mass, and hypercortisolemia. IGF-I, a known bone trophic factor, is reduced despite elevated growth hormone (GH) levels, leading to an acquired GH resistant state. Elevated ghrelin and peptide YY levels may also contribute to impaired bone metabolism. Weight recovery is associated with recovery of BMD but this is often partial, and long-term and sustained weight recovery may be necessary before significant improvements are observed. Anti-resorptive therapies have been studied in AN with conflicting results. Oral estrogen does not increase BMD or prevent bone loss in AN. The combination of bone anabolic and anti-resorptive therapy (rhIGF-I with oral estrogen), however, did result in a significant increase in BMD in a study of adult women with AN. A better understanding of the pathophysiology of low BMD in AN, and development of effective therapeutic strategies is critical. This is particularly so for adolescents, who are in the process of accruing peak bone mass, and in whom a failure to attain peak bone mass may occur in AN in addition to loss of established bone.

    Topics: Androgens; Anorexia Nervosa; Bone Density Conservation Agents; Calcium; Diphosphonates; Eating; Estrogen Replacement Therapy; Ghrelin; Humans; Hypogonadism; Insulin-Like Growth Factor I; Leptin; Malnutrition; Motor Activity; Osteoporosis; Peptide Hormones; Peptide YY; Recombinant Proteins; Vitamin D

2006